

**Electronic Trial Master File (eTMF) Systems Market by Offering (Integrated, Standalone), Function (Analytic, Compliance, Workflow, Audit), Therapeutic (Onco, Cardio, Neuro), End User (Pharma, Biotech, MedDevice), Phase, Region - Global Forecast to 2030**

Market Report | 2025-10-27 | 337 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The global eTMF systems market is projected to reach USD 2.49 billion by 2030, up from USD 1.36 billion in 2025, at a high CAGR of 12.8% during the forecast period. The market is progressing steadily, driven by the growing demand for streamlined clinical trial management, regulatory compliance, and data integrity. The increasing adoption of digital and cloud-based solutions, coupled with the need for real-time document tracking, automated reporting, and enhanced collaboration across study sites, is fueling growth. Highlighting efficiency benefits, a recent Frost & Sullivan (2024) study estimates that eTMF systems can reduce audit and site preparation time by up to 30%, accelerating drug approval processes. Moreover, rising investments in pharmaceutical and biotechnology research, along with the complexity of global clinical trials, are accelerating the adoption of eTMF systems worldwide.

<https://mnmimg.marketsandmarkets.com/Images/electronic-trial-master-file-system-market-overview.webp>

"The cloud-based segment, under the eTMF systems market, is the largest segment during the forecast period." Based on deployment, the cloud-based segment accounted for the largest share of the eTMF systems market, driven by the growing preference for scalable, secure, and accessible clinical trial management solutions. Cloud-based eTMF systems enable real-time document access, centralized collaboration across multiple study sites, and seamless integration with other digital health platforms. These solutions reduce IT infrastructure costs, simplify system maintenance, and ensure compliance with regulatory requirements through automated updates and audit-ready documentation. The increasing complexity of clinical trials,

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

coupled with the need for remote monitoring and efficient data management, is driving the global adoption of cloud-based eTMF systems among pharmaceutical, biotechnology, and contract research organizations.

"Based on the end user, the contract research organizations (CROs) segment is expected to register the fastest growth during the forecast period."

In 2024, based on end user, the contract research organizations (CROs) segment is expected to register the fastest growth in the eTMF systems market during the forecast period. The rising number of outsourced clinical trials and increasing complexity of study protocols are driving CROs to adopt eTMF systems for efficient and compliant document management. These systems enable the real-time tracking of trial documents, streamline workflows, and enhance collaboration across multiple study sites. Moreover, CROs benefit from enhanced data integrity, audit readiness, and regulatory compliance offered by eTMF solutions. Growing demand for faster trial execution and cost-effective operations is further fueling the rapid adoption of eTMF systems by CROs globally.

"Asia Pacific to witness the highest growth rate during the forecast period."

Asia Pacific is expected to witness the highest growth rate in the eTMF systems market during the forecast period, driven by the rapid expansion of the pharmaceutical and biotechnology sectors across the region. Increasing clinical trial activities, rising outsourcing of trials to Contract Research Organizations (CROs), and growing adoption of digital solutions for efficient trial management are key factors fueling market growth. Moreover, improvements in healthcare infrastructure, favorable government initiatives, and rising investment in clinical research are supporting the adoption of advanced eTMF systems. Cloud-based platforms, analytics, and reporting functionalities are being increasingly implemented to ensure compliance, streamline workflows, and enhance data integrity. The combination of these factors positions the Asia Pacific as the fastest-growing regional market globally.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the authentication and brand protection marketplace. The breakdown of primary participants is as mentioned below:

-□By Company Type - Tier 1: 48%, Tier 2: 36%, and Tier 3: 16%

-□By Designation - Directors: 15%, Managers: 10%, and Others: 75%

-□By Region - North America: 39%, Europe: 31%, Asia Pacific: 21, Latin America: 6%, Middle East & Africa: 3%

#### Key Players in the Market

The key players operating in the eTMF systems market include Veeva Systems (US), Oracle (US), IQVIA (US), Medidata (Dassault Systemes) (US), TransPerfect (US), Phlexglobal (Cencora, Inc.) (UK), ArisGlobal (US), MasterControl Solutions, Inc. (US), Ennov (UK), Montrium Inc. (Canada), SureClinical Inc. (US), Florence Healthcare (US), Egnyte, Inc. (US), Cloudbyz (US), myClin Clinical Research LLC. (US), Octalsoft (US), Crucial Data Solutions (US), DataRiver S.r.l. (Italy), EXTEDO (Bertelsmann SE & Co. KGaA) (Germany), Aurea, Inc. (US), Agatha Inc. (Japan), EvidentIQ (Germany), Clinion (US), Anju Software Inc. (US), Clinevo Technologies (US).

#### Research Coverage:

The report analyzes the eTMF systems market, aiming to estimate the market size and future growth potential of various market segments based on offering, functionality, deployment, therapeutic area, trial phase, end user, and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

#### Reasons to Buy the Report

This report will benefit established firms as well as new entrants and smaller firms in gauging the market pulse, which in turn will help them capture a greater share of the market. Firms purchasing the report can use one or a combination of the following strategies to strengthen their market positions.

This report provides insights into:

-□Analysis of key drivers (rising number of clinical trials, regulatory compliance and inspection readiness, real-time data management and analysis, support for decentralized and global trials, adoption of cloud-based and automated solutions), restraints (high setup and licensing costs, resistance to change from traditional paper-based systems), opportunities (AI-driven

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

automation & risk-based document management, predictive analytics for compliance & risk management), and challenges (data security & cybersecurity risks, interoperability issues with legacy systems) influencing the growth of the eTMF systems market

- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the eTMF systems market
- Market Development: Comprehensive information on the lucrative emerging markets, offering, functionality, deployment, therapeutic area, trial phase, end user, and region
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the eTMF systems market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the eTMF systems market, like Veeva Systems (US), Oracle (US), IQVIA (US), Medidata (US), and Transperfect (US)

**Table of Contents:**

- 1□INTRODUCTION□32
- 1.1□STUDY OBJECTIVES□32
- 1.2□MARKET DEFINITION□32
- 1.3□MARKET SCOPE□33
- 1.3.1□MARKET SEGMENTATION AND REGIONAL SCOPE□33
- 1.3.2□INCLUSIONS AND EXCLUSIONS□34
- 1.3.3□YEARS CONSIDERED□35
- 1.4□CURRENCY CONSIDERED□35
- 1.5□STAKEHOLDERS□35
- 1.6□SUMMARY OF CHANGES□36
- 2□RESEARCH METHODOLOGY□37
- 2.1□RESEARCH APPROACH□37
- 2.1.1□SECONDARY RESEARCH□38
- 2.1.1.1□Key data from secondary sources□39
- 2.1.2□PRIMARY RESEARCH□39
- 2.1.2.1□Primary sources□40
- 2.1.2.2□Key data from primary sources□41
- 2.1.2.3□Breakdown of primaries□41
- 2.1.2.4□Insights from primary experts□42
- 2.2□RESEARCH METHODOLOGY DESIGN□42
- 2.3□MARKET SIZE ESTIMATION□43
- 2.4□MARKET BREAKDOWN AND DATA TRIANGULATION□47
- 2.5□MARKET SHARE ESTIMATION□47
- 2.6□RESEARCH ASSUMPTIONS□48
- 2.7□RESEARCH LIMITATIONS□48
- 2.8□RISK ASSESSMENT□48
- 3□EXECUTIVE SUMMARY□49
- 4□PREMIUM INSIGHTS□55
- 4.1□ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET□55
- 4.2□NORTH AMERICA: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING AND REGION□56
- 4.3□ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES□57
- 4.4□REGIONAL MIX: ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET (2023-2030)□57

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

4.5	ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET: DEVELOPED VS. EMERGING ECONOMIES, 2025 VS. 2030 (USD MILLION)	58
5	MARKET OVERVIEW	59
5.1	INTRODUCTION	59
5.2	MARKET DYNAMICS	59
5.2.1	DRIVERS	60
5.2.1.1	Rising number of clinical trials	60
5.2.1.2	Growing regulatory scrutiny and need for inspection readiness	61
5.2.1.3	Increasing complexity of clinical trials	62
5.2.1.4	Growing shift toward decentralized and global clinical trial methodologies	62
5.2.1.5	Increasing adoption of cloud-based and automated solutions	63
5.2.2	RESTRAINTS	63
5.2.2.1	High setup and licensing costs	63
5.2.2.2	Resistance to change from traditional paper-based systems	64
5.2.3	OPPORTUNITIES	64
5.2.3.1	Integration of artificial intelligence and risk-based approaches	64
5.2.3.2	Predictive analytics for compliance & risk management	65
5.2.4	CHALLENGES	65
5.2.4.1	Data security & cybersecurity risks	65
5.2.4.2	Interoperability challenges with legacy systems	67
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS	67
5.4	INDUSTRY TRENDS	68
5.4.1	SHIFT FROM PAPER-BASED TO DIGITAL TRIAL DOCUMENTATION	68
5.4.2	ADOPTION OF CLOUD-BASED AND SCALABLE SOLUTIONS	69
5.4.3	INTEGRATION WITH OTHER CLINICAL SYSTEMS	69
5.4.4	USE OF ARTIFICIAL INTELLIGENCE AND AUTOMATION	69
5.4.5	FOCUS ON REGULATORY COMPLIANCE AND INSPECTION READINESS	69
5.5	REGULATORY LANDSCAPE	69
5.5.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	70
5.5.2	REGULATORY ANALYSIS	73
5.5.2.1	North America	73
5.5.2.2	Europe	73
5.5.2.3	Asia Pacific	74
5.5.2.4	Latin America	75
5.5.2.5	Middle East & Africa	75
5.6	PRICING ANALYSIS	75
5.6.1	INDICATIVE PRICING ANALYSIS, BY KEY PLAYER	76
5.6.2	INDICATIVE PRICING ANALYSIS, BY REGION	77
5.6.3	PRICING MODELS	77
?		
5.7	VALUE CHAIN ANALYSIS	78
5.7.1	PRODUCT DESIGN & DEVELOPMENT	79
5.7.2	SYSTEM INTEGRATION & WORKFLOW CUSTOMIZATION	79
5.7.3	IMPLEMENTATION	80
5.7.4	COMPLIANCE MONITORING & AUDIT READINESS	80
5.7.5	POST-SALES SERVICES	80
5.8	ECOSYSTEM ANALYSIS	80

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.9	INVESTMENT AND FUNDING SCENARIO	83
5.10	TECHNOLOGY ANALYSIS	83
5.10.1	KEY TECHNOLOGIES	83
5.10.1.1	Document Management Systems (DMS)	83
5.10.1.2	Workflow automation and collaboration tools	84
5.10.1.3	Compliance and regulatory tools	84
5.10.1.4	Cloud storage and security	84
5.10.2	COMPLEMENTARY TECHNOLOGIES	84
5.10.2.1	Artificial Intelligence (AI)/Machine Learning (ML)	84
5.10.2.2	Blockchain	85
5.10.2.3	Robotic Process Automation (RPA)	85
5.10.2.4	Collaboration and communication tools	85
5.10.2.5	Mobile applications	85
5.10.3	ADJACENT TECHNOLOGIES	86
5.10.3.1	CLINICAL TRIAL MANAGEMENT SYSTEMS (CTMS)	86
5.10.3.2	RANDOMIZATION & TRIAL SUPPLY MANAGEMENT (RTSM/IWRS)	86
5.10.3.3	ELECTRONIC DATA CAPTURE (EDC)	86
5.10.3.4	ECONSENT PLATFORMS	86
5.10.3.5	ESOURCE/REMOTE SOURCE DATA CAPTURE	86
5.11	PATENT ANALYSIS	87
5.12	KEY CONFERENCES AND EVENTS, 2025-2026	89
5.13	CASE STUDY ANALYSIS	90
5.13.1	CASE STUDY 1: ENHANCED CLINICAL EFFICIENCY AND INSPECTION READINESS THROUGH VEEVA ETMF AND CTMS	90
5.13.2	CASE STUDY 2: STREAMLINED CLINICAL TRIAL OPERATIONS WITH ORACLE SIEBEL CTMS	90
5.13.3	CASE STUDY 3: TRANSITION TOWARD ELECTRONIC TMF FOR INSPECTION READINESS	91
5.14	PORTER'S FIVE FORCES ANALYSIS	91
5.14.1	BARGAINING POWER OF SUPPLIERS	93
5.14.2	BARGAINING POWER OF BUYERS	93
5.14.3	THREAT OF NEW ENTRANTS	93
5.14.4	THREAT OF SUBSTITUTES	93
5.14.5	INTENSITY OF COMPETITIVE RIVALRY	93
	?	
5.15	KEY STAKEHOLDERS AND BUYING CRITERIA	93
5.15.1	KEY STAKEHOLDERS IN BUYING PROCESS	94
5.15.2	BUYING CRITERIA	95
5.16	UNMET NEEDS ANALYSIS	95
5.16.1	CURRENT UNMET NEEDS	95
5.16.2	END-USER EXPECTATIONS	96
5.17	BUSINESS MODELS	98
5.17.1	SUBSCRIPTION-BASED (SAAS) MODEL	98
5.17.2	LICENSING MODEL	98
5.17.3	PAY-PER-USE MODEL	98
5.17.4	FREEMIUM MODEL	98
5.17.5	HYBRID MODEL	98
5.18	IMPACT OF AI/GEN AI ON ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET	98
5.18.1	INTRODUCTION	98
5.18.2	MARKET POTENTIAL OF AI/GEN AI ON ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET	99

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.18.3	CASE STUDY RELATED TO AI/GEN AI IMPLEMENTATION	100
5.18.3.1	AI-powered eTMF automation for CRO document processing	100
5.18.4	IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS	101
5.18.4.1	Clinical trial services	101
5.18.4.2	eClinical solutions	101
5.18.4.3	AI in clinical trials	102
5.18.5	USER READINESS AND IMPACT ASSESSMENT	102
5.18.5.1	User readiness	102
5.18.5.1.1	User A: Pharmaceutical & Biotechnology Companies	102
5.18.5.1.2	User B: Contract Research Organizations (CROs)	102
5.18.5.2	Impact assessment	103
5.18.5.2.1	User A: Pharmaceutical & Biotechnology Companies	103
5.18.5.2.2	User B: Contract Research Organizations (CROs)	103
5.19	IMPACT OF 2025 US TARIFFS ON ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET	104
5.19.1	INTRODUCTION	104
5.19.2	KEY TARIFF RATES	104
5.19.3	PRICE IMPACT ANALYSIS	105
5.19.4	IMPACT ON COUNTRY/REGION	105
5.19.4.1	US	105
5.19.4.2	Europe	106
5.19.4.3	Asia Pacific	106
5.19.5	IMPACT ON END-USE INDUSTRIES	106
5.19.5.1	Pharmaceutical & biotechnology companies	106
5.19.5.2	Contract Research Organizations (CROs)	106
?		
6	ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY OFFERING	107
6.1	INTRODUCTION	108
6.2	SOFTWARE	108
6.2.1	STANDALONE ETMF SOFTWARE	110
6.2.1.1	Easy scalability, quick implementation timelines, and reduced IT infrastructure requirements to drive market	110
6.2.2	INTEGRATED ETMF SOFTWARE	110
6.2.2.1	Shift toward unified eClinical ecosystems, cloud-based platforms, and advanced analytics capabilities to propel market	110
6.3	SERVICES	111
6.3.1	RISING COMPLEXITY OF GLOBAL AND DECENTRALIZED TRIALS TO EXPEDITE GROWTH	111
7	ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS, BY FUNCTIONALITY	113
7.1	INTRODUCTION	114
7.2	DOCUMENT MANAGEMENT	114
7.2.1	NEED FOR ADVANCED DOCUMENT MANAGEMENT AND ENHANCED OPERATIONAL TRANSPARENCY TO BOLSTER GROWTH	114
7.3	WORKFLOW & COLLABORATION TOOLS	115
7.3.1	ABILITY TO OFFER STRUCTURED, LARGE-SCALE INFORMATION ON HEALTHCARE SERVICES, UTILIZATION PATTERNS, AND ASSOCIATED COSTS TO BOOST MARKET	115
7.4	COMPLIANCE & AUDIT MANAGEMENT	116
7.4.1	EXPANDING COMPLEXITY OF MULTI-SITE AND HYBRID CLINICAL TRIALS TO CONTRIBUTE TO GROWTH	116
7.5	ANALYTICS & REPORTING	118
7.5.1	INCREASING SHIFT TOWARD DATA-DRIVEN QUALITY MANAGEMENT TO STIMULATE GROWTH	118
7.6	INTEGRATION WITH OTHER ECLINICAL SYSTEMS	119
7.6.1	GROWING ADOPTION OF CLOUD-BASED AND API-ENABLED PLATFORMS TO PROPEL MARKET	119

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY DEPLOYMENT 121

8.1 INTRODUCTION 122

8.2 CLOUD-BASED DEPLOYMENT 122

8.2.1 RISE OF DECENTRALIZED AND HYBRID CLINICAL TRIAL MODELS TO PROMOTE GROWTH 122

8.3 ON-PREMISES DEPLOYMENT 123

8.3.1 NEED FOR HIGHLY CUSTOMIZED CONFIGURATIONS AND INTEGRATION WITH EXISTING LEGACY SYSTEMS TO AID GROWTH 123

?

9 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY THERAPEUTIC AREA 125

9.1 INTRODUCTION 126

9.2 ONCOLOGY 126

9.2.1 INCREASING SHIFT TOWARD DECENTRALIZED AND HYBRID ONCOLOGY TRIALS TO FACILITATE GROWTH 126

9.3 CARDIOVASCULAR DISEASES 127

9.3.1 SURGE IN TRIAL ACTIVITY TO CONTRIBUTE TO GROWTH 127

9.4 RESPIRATORY DISEASES 129

9.4.1 GROWING EMPHASIS ON DEVELOPING NOVEL BIOLOGICS, INHALATION THERAPIES, VACCINES, AND PRECISION MEDICINE APPROACHES TO BOOST MARKET 129

9.5 GASTROINTESTINAL DISORDERS 130

9.5.1 RISING GLOBAL BURDEN OF GASTROINTESTINAL DISORDERS TO AUGMENT GROWTH 130

9.6 NEUROLOGICAL DISORDERS 131

9.6.1 RISE IN NEUROLOGICAL RESEARCH ACTIVITY TO STIMULATE GROWTH 131

9.7 OTHER THERAPEUTIC AREAS 132

10 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY TRIAL PHASE 134

10.1 INTRODUCTION 135

10.2 PHASE I 135

10.2.1 GROWING EARLY-STAGE OUTSOURCING TO DRIVE MARKET 135

10.3 PHASE II 136

10.3.1 INCREASED STUDY ENDPOINTS AND COMPLEX PROTOCOL REQUIREMENTS TO EXPEDITE GROWTH 136

10.4 PHASE III 137

10.4.1 NEED TO ENSURE GLOBAL COMPLIANCE AND MAINTAIN END-TO-END DOCUMENT LIFECYCLE TO BOOST MARKET 137

10.5 PHASE IV 138

10.5.1 INCREASING EMPHASIS ON REAL-WORLD EVIDENCE GENERATION AND PHARMACOVIGILANCE TO SUPPORT GROWTH 138

11 ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY END USER 140

11.1 INTRODUCTION 141

11.2 PHARMACEUTICAL & BIOTECH COMPANIES 141

11.2.1 RISING REGULATORY SCRUTINY TO ENCOURAGE GROWTH 141

11.3 MEDICAL DEVICE COMPANIES 142

11.3.1 GROWING EMPHASIS ON IMPROVED PATIENT SAFETY OUTCOMES AND AUTOMATED QUALITY CHECKS TO BOOST MARKET 142

11.4 CONTRACT RESEARCH ORGANIZATIONS (CRO) 144

11.4.1 INCREASING FINANCIAL PRESSURE TO CONTROL RISING HEALTHCARE COSTS AND IMPROVE RETURN ON INVESTMENT TO SPUR GROWTH 144

?

11.5 ACADEMIC & HEALTHCARE RESEARCH INSTITUTIONS 145

11.5.1 NEED FOR DATA INTEGRITY, ACCURATE AUDIT TRAILS, AND CONSISTENT DOCUMENTATION PRACTICES TO FUEL MARKET 145

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.6	GOVERNMENT & NON-PROFIT ORGANIZATIONS	146
11.6.1	INCREASING EMPHASIS ON REGULATORY COMPLIANCE, DATA TRANSPARENCY, AND EFFICIENT RESOURCE UTILIZATION TO DRIVE MARKET	146
12	ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET, BY REGION	148
12.1	INTRODUCTION	149
12.2	NORTH AMERICA	150
12.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	151
12.2.2	US	155
12.2.2.1	Robust clinical research ecosystem and regulatory frameworks to aid growth	155
12.2.3	CANADA	159
12.2.3.1	Growing emphasis on compliance and digital clinical operations to drive market	159
12.3	EUROPE	162
12.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	163
12.3.2	GERMANY	166
12.3.2.1	Increasing transition toward digital documentation and regulatory harmonization to fuel market	166
12.3.3	FRANCE	170
12.3.3.1	Expanding clinical research infrastructure to contribute to growth	170
12.3.4	UK	173
12.3.4.1	Ongoing regulatory transition to expedite growth	173
12.3.5	ITALY	177
12.3.5.1	Fragmented digital infrastructure to limit growth	177
12.3.6	SPAIN	180
12.3.6.1	Growing clinical trial volume and continued investment in digital research infrastructure to boost market	180
12.3.7	REST OF EUROPE	184
12.4	ASIA PACIFIC	188
12.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	188
12.4.2	CHINA	192
12.4.2.1	Growing shift toward global compliance frameworks to fuel market	192
12.4.3	JAPAN	196
12.4.3.1	Rising demand for eTMF systems amid digital trial transformation to boost market	196
12.4.4	INDIA	199
12.4.4.1	Rising number of eTMF-management certification programs to promote growth	199
12.4.5	SOUTH KOREA	203
12.4.5.1	Continued support for biopharmaceutical innovations to drive market	203
12.4.6	AUSTRALIA	206
12.4.6.1	Increased digital health and clinical research modernization initiatives to bolster growth	206
12.4.7	REST OF ASIA PACIFIC	210
12.5	LATIN AMERICA	213
12.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	214
12.5.2	BRAZIL	218
12.5.2.1	Growing participation in global multicenter clinical trials to fuel market	218
12.5.3	MEXICO	221
12.5.3.1	Growing number of research-active hospitals to fuel market	221
12.5.4	REST OF LATIN AMERICA	225
12.6	MIDDLE EAST & AFRICA	228
12.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA	229
12.6.2	GCC COUNTRIES	233

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.6.2.1 Saudi Arabia 236
- 12.6.2.1.1 Growing emphasis on transparency, quality assurance, and digital oversight to propel market 236
- 12.6.2.2 UAE 240
- 12.6.2.2.1 Favorable digital health transformation to aid growth 240
- 12.6.2.3 Rest of GCC countries 243
- 12.6.3 REST OF MIDDLE EAST & AFRICA 247
- 13 COMPETITIVE LANDSCAPE 252
- 13.1 OVERVIEW 252
- 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 252
- 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ELECTRONIC TRIAL MASTER FILE (ETMF) SYSTEMS MARKET 252
- 13.3 REVENUE SHARE ANALYSIS, 2020-2024 254
- 13.4 MARKET SHARE ANALYSIS, 2024 255
- 13.5 BRAND/SOFTWARE COMPARISON 257
- 13.6 COMPANY VALUATION AND FINANCIAL METRICS 258
- 13.6.1 COMPANY VALUATION 258
- 13.6.2 FINANCIAL METRICS 258
- 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS 259
- 13.7.1 STARS 259
- 13.7.2 EMERGING LEADERS 259
- 13.7.3 PERVASIVE PLAYERS 260
- 13.7.4 PARTICIPANTS 260
- ?
- 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 261
- 13.7.5.1 Company footprint 261
- 13.7.5.2 Region footprint 262
- 13.7.5.3 Offering footprint 263
- 13.7.5.4 Functionality footprint 264
- 13.7.5.5 End-user footprint 265
- 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 266
- 13.8.1 PROGRESSIVE COMPANIES 266
- 13.8.2 RESPONSIVE COMPANIES 266
- 13.8.3 DYNAMIC COMPANIES 266
- 13.8.4 STARTING BLOCKS 266
- 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 268
- 13.8.5.1 Detailed list of key startups/SMEs 268
- 13.8.5.2 Competitive benchmarking of startups/SMEs 268
- 13.9 COMPETITIVE SCENARIO 269
- 13.9.1 PRODUCT LAUNCHES AND ENHANCEMENTS 269
- 13.9.2 DEALS 270
- 13.9.3 OTHER DEVELOPMENTS 271
- 14 COMPANY PROFILES 272
- 14.1 KEY PLAYERS 272
- 14.1.1 VEEVA SYSTEMS 272
- 14.1.1.1 Business overview 272
- 14.1.1.2 Products offered 273
- 14.1.1.3 Recent developments 274
- 14.1.1.3.1 Product launches and enhancements 274

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.1.1.3.2 Deals 274
- 14.1.1.4 MnM view 275
  - 14.1.1.4.1 Right to win 275
  - 14.1.1.4.2 Strategic choices 275
  - 14.1.1.4.3 Weaknesses and competitive threats 275
- 14.1.2 ORACLE 276
  - 14.1.2.1 Business overview 276
  - 14.1.2.2 Products offered 277
    - 14.1.2.3 Recent developments 278
      - 14.1.2.3.1 Product launches and enhancements 278
      - 14.1.2.3.2 Deals 278
      - 14.1.2.4 MnM view 278
        - 14.1.2.4.1 Right to win 278
        - 14.1.2.4.2 Strategic choices 278
        - 14.1.2.4.3 Weaknesses and competitive threats 279
- 14.1.3 IQVIA 280
  - 14.1.3.1 Business overview 280
  - 14.1.3.2 Products offered 281
    - 14.1.3.3 Recent developments 282
      - 14.1.3.3.1 Product launches and enhancements 282
      - 14.1.3.3.2 Deals 283
    - 14.1.3.4 MnM view 283
      - 14.1.3.4.1 Right to win 283
      - 14.1.3.4.2 Strategic choices 283
      - 14.1.3.4.3 Weaknesses and competitive threats 284
- 14.1.4 MEDIDATA (DASSAULT SYSTEMES) 285
  - 14.1.4.1 Business overview 285
  - 14.1.4.2 Products offered 286
    - 14.1.4.3 Recent developments 287
      - 14.1.4.3.1 Product launches and enhancements 287
      - 14.1.4.3.2 Deals 287
    - 14.1.4.4 MnM view 288
      - 14.1.4.4.1 Right to win 288
      - 14.1.4.4.2 Strategic choices 288
      - 14.1.4.4.3 Weaknesses and competitive threats 288
- 14.1.5 TRANSPERFECT 289
  - 14.1.5.1 Business overview 289
  - 14.1.5.2 Products offered 289
    - 14.1.5.3 Recent developments 290
      - 14.1.5.3.1 Product launches and enhancements 290
      - 14.1.5.3.2 Deals 290
    - 14.1.5.4 MnM view 291
      - 14.1.5.4.1 Right to win 291
      - 14.1.5.4.2 Strategic choices 291
      - 14.1.5.4.3 Weaknesses and competitive threats 291
- 14.1.6 PHLEXGLOBAL (CENCORA, INC.) 292

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14.1.6.1	Business overview	292
14.1.6.2	Products offered	293
14.1.6.3	Recent developments	294
14.1.6.3.1	Product launches and enhancements	294
14.1.6.3.2	Deals	295
14.1.7	ARISGLOBAL	296
14.1.7.1	Business overview	296
14.1.7.2	Products offered	296
14.1.7.3	Recent developments	297
14.1.7.3.1	Deals	297
?		
14.1.8	MASTERCONTROL SOLUTIONS, INC.	298
14.1.8.1	Business overview	298
14.1.8.2	Products offered	298
14.1.8.3	Recent developments	299
14.1.8.3.1	Deals	299
14.1.8.3.2	Other developments	299
14.1.9	ENNOV	300
14.1.9.1	Business overview	300
14.1.9.2	Products offered	301
14.1.9.3	Recent developments	301
14.1.9.3.1	Product launches and enhancements	301
14.1.9.3.2	Deals	302
14.1.10	MONTRIUM INC.	303
14.1.10.1	Business overview	303
14.1.10.2	Products offered	303
14.1.10.3	Recent developments	304
14.1.10.3.1	Product launches and enhancements	304
14.1.10.3.2	Deals	304
14.1.11	EXTEDO	305
14.1.11.1	Business overview	305
14.1.11.2	Products offered	306
14.1.11.3	Recent developments	307
14.1.11.3.1	Product launches and enhancements	307
14.1.11.3.2	Deals	307
14.1.12	SURECLINICAL INC.	308
14.1.12.1	Business overview	308
14.1.12.2	Products offered	308
14.1.12.3	Recent developments	309
14.1.12.3.1	Deals	309
14.1.13	FLORENCE HEALTHCARE	310
14.1.13.1	Business overview	310
14.1.13.2	Products offered	310
14.1.13.3	Recent developments	311
14.1.13.3.1	Product launches and enhancements	311
14.1.13.3.2	Deals	311
14.1.14	EGNYTE, INC.	312

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.1.14.1 Business overview 312
- 14.1.14.2 Products offered 312
- 14.1.14.3 Recent developments 313
  - 14.1.14.3.1 Product launches and enhancements 313
  - 14.1.14.3.2 Deals 313
  - 14.1.14.3.3 Other developments 314
- 14.1.15 CLOUDBYZ 315
  - 14.1.15.1 Business overview 315
  - 14.1.15.2 Products offered 315
  - 14.1.15.3 Recent developments 316
    - 14.1.15.3.1 Deals 316
- 14.1.16 MYCLIN CLINICAL RESEARCH LLC 317
  - 14.1.16.1 Business overview 317
  - 14.1.16.2 Products offered 317
- 14.1.17 OCTALSOFT 318
  - 14.1.17.1 Business overview 318
  - 14.1.17.2 Products offered 318
- 14.1.18 CRUCIAL DATA SOLUTIONS 319
  - 14.1.18.1 Business overview 319
  - 14.1.18.2 Products offered 319
  - 14.1.18.3 Recent developments 320
    - 14.1.18.3.1 Product launches and enhancements 320
    - 14.1.18.3.2 Deals 320
- 14.1.19 DATARIVER S.R.L. 321
  - 14.1.19.1 Business overview 321
  - 14.1.19.2 Products offered 321
- 14.1.20 AUREA, INC. 322
  - 14.1.20.1 Business overview 322
  - 14.1.20.2 Products offered 322
- 14.2 OTHER PLAYERS 323
  - 14.2.1 AGATHA INC. 323
  - 14.2.2 EVIDENTIQ 324
  - 14.2.3 CLINION 325
  - 14.2.4 ANJU SOFTWARE 326
  - 14.2.5 CLINEVO TECHNOLOGIES 327
- 15 APPENDIX 328
  - 15.1 DISCUSSION GUIDE 328
  - 15.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL 333
  - 15.3 CUSTOMIZATION OPTIONS 335
  - 15.4 RELATED REPORTS 335
  - 15.5 AUTHOR DETAILS 336

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Electronic Trial Master File (eTMF) Systems Market by Offering (Integrated, Standalone), Function (Analytic, Compliance, Workflow, Audit), Therapeutic (Onco, Cardio, Neuro), End User (Pharma, Biotech, MedDevice), Phase, Region - Global Forecast to 2030**

Market Report | 2025-10-27 | 337 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scottis-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scottis-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scottis-international.com

www.scottis-international.com

Zip Code\*

Country\*

Date

2026-03-16

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com